353 citations
,
February 2022 in “Nature Immunology”
This review explores post-COVID-19 syndromes and the underlying mechanisms, including persistent inflammation, autoimmunity, and possible viral reservoirs, but reports no new clinical results.
In this study, 70.7% of long-COVID patients reported persistent symptoms three months post-infection, with chronic fatigue, cough, and brain fog being the most common, and female gender and severe initial COVID-19 were identified as risk factors.
44 citations
,
April 2023 in “Frontiers in Molecular Biosciences”
This narrative review outlines the diverse symptoms and possible mechanisms behind longCOVID, such as immune dysregulation and viral persistence, while discussing ongoing and potential treatments, highlighting the current lack of proven effective therapies.
17 citations
,
September 2024 in “The Indian Journal of Medical Research”
This source explores longCOVID syndrome and identifies risk factors like older age, female gender, and comorbidities such as diabetes. It mentions potential diagnostic biomarkers, highlights ongoing clinical trials, and emphasizes the importance of vaccines and rehabilitation in managing longCOVID.
14 citations
,
June 2023 in “Journal of Infection and Public Health”
This study observed a low rate of long-COVID lasting more than three months among mostly vaccinated healthcare workers during the Omicron wave, suggesting that further research is needed to assess the impact of different vaccines on long-COVID-19 in this group.
The user experienced hair thinning, possibly due to longCOVID and prediabetes, and saw regrowth after dietary changes and using biotin shampoo. They are taking vitamins and noticed significant hair regrowth, especially at the widow's peak.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
The conversation is about long-term finasteride use for hair loss, with users discussing periods of improvement and worsening, and considering switching to dutasteride. Other treatments mentioned include minoxidil, red light therapy, microneedling, and scalp massaging.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
How long should I wait to see if Alfatradiol is working for me?The one randomised trial and community reports both point to waiting at least 3 to 6 months, and to expecting stabilised shedding rather than regrowth — the published evidence for alfatradiol is a single six-month study in about 100 women.
How long does it take for clascoterone to show results on hair growth?Clascoterone is not approved for hair loss; it is investigational. In the trials reported so far, application was twice daily and increases in terminal hair count were reported at around 6 months, with more sustained change reported between 6 and 12 months.
How long does it take for cyproterone to work on hair loss?There is no reliable published figure for how fast cyproterone works on hair loss: the hair cycle means nothing shows for months, the one randomised trial assessed women at twelve months, and community reports range from about six months to two years — with some people seeing no change at all.
How long does it take to see results with Fluridil in progressive hair loss?No published study measures how long fluridil takes to show a visible change; the single double-blind trial (43 men, 2% fluridil) reported a rise in the proportion of hairs in the growth phase at three and nine months, and community reports describe stabilization rather than regrowth.